NasdaqGM - Nasdaq Real Time Price USD

MediciNova, Inc. (MNOV)

1.3100 -0.0100 (-0.76%)
As of 12:48 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MNOV

Recent News: MNOV

View More
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
GlobeNewswire 23 days ago
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
GlobeNewswire 30 days ago
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
GlobeNewswire last month
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
Simply Wall St. last month
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
GlobeNewswire last month
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…

MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
Zacks Small Cap Research last month
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
GlobeNewswire 3 months ago
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
GlobeNewswire 4 months ago
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
GlobeNewswire 4 months ago
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
Zacks Small Cap Research 4 months ago
The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable

The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable
Simply Wall St. 5 months ago
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
GlobeNewswire 5 months ago
View More

Related Tickers

CNTB Connect Biopharma Holdings Limited
1.3594
+0.70%
 
ACOGF Alpha Cognition Inc.
0.4928
-0.44%
 
ATHA Athira Pharma, Inc.
1.9400
+1.04%
 
ACIU AC Immune SA
2.3800
+3.93%
 
INAB IN8bio, Inc.
1.0099
-2.89%
 
RIGL Rigel Pharmaceuticals, Inc.
1.1150
+1.36%
 
LYEL Lyell Immunopharma, Inc.
2.1450
-2.50%
 
KZR Kezar Life Sciences, Inc.
0.8046
+1.84%
 
KZIA Kazia Therapeutics Limited
0.3890
+6.63%
 
PBM Psyence Biomedical Ltd.
0.8500
+2.41%